Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Bayer Flatly Denies Its Employee’s Allegations in 2nd Oral Proceedings for Damage Suit
The second oral argument was held at the Tokyo District Court on July 17 in a damage suit filed by an employee of Bayer Yakuhin claiming that he suffered emotional distress over a scandal involving the company’s flagship anticoagulant Xarelto…
To read the full story
Related Article
- Bayer, Employee Reach Settlement over Xarelto Scandal
July 28, 2022
- High Court Verdict for Bayer Employee Damage Suit Set for Sept. 7, Settlement Eyed Too
July 5, 2022
- Bayer Employee Loses in Damage Suit over Xarelto Scandal
February 15, 2022
- 1st Oral Proceedings Held for Bayer Employee Damage Suit
May 21, 2019
- Employee Sues Bayer Japan for Emotional Distress over Xarelto Scandal
March 19, 2019
- Whistleblower Bayer Rep Raps “No Instruction” Finding in Xarelto Scandal Probe
July 21, 2017
- Probe Finds No HQ Instruction for Improper Patient Info Acquisition in Xarelto Surveys, Bayer Execs Take 3-Month Pay Cuts
July 18, 2017
- “Headquarters Involvement Clear” in Access to Patient Medical Charts by Bayer Sales Reps: Attorney for Whistleblower
April 20, 2017
- Bayer Apologizes for Employees’ “Improper” Involvement in Xarelto Survey, Whistleblower Says He Browsed Charts for over 200 Patients
April 12, 2017
BUSINESS
- Nxera Cuts Executive Pay as Losses Widen
February 16, 2026
- Otsuka Pharma Sales Rise 7.1% in 2025, Driven by Rexulti
February 16, 2026
- Gilead Japan Files Trodelvy for 1st-Line TNBC in PD-1/PD-L1-Ineligible Patients
February 16, 2026
- FRONTEO to Back Biotech Startups with AI and Capital as Third Biz Leg
February 13, 2026
- Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
February 13, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…